The Research and Development Team at NewLimit focuses on pioneering innovative therapies to combat age-related diseases by reprogramming the epigenome. Utilizing advanced techniques in functional genomics and machine learning, the team conducts large-scale experiments to uncover the mechanisms of epigenetic aging. Their collaborative efforts drive the discovery and development of groundbreaking medicines aimed at enhancing human healthspan.